药理学阻断的微纤维相关蛋白4减少了视网膜新血管生成和血管泄漏
Anders Schlosser1, Bartosz Pilecki1, Claire Allen2
1Department of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
概括
一种抗微纤维相关蛋白4 (MFAP4) 抗体hAS0326有效治疗视网膜新血管化和血管泄漏. 这种抗体阻断了整合素的结合,显示出对视力丧失疾病的希望.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 神经血管与年龄相关的黄斑退化和糖尿病黄斑胀导致显著的视力丧失.
- 视网膜新血管化和血管泄漏是这些疾病的关键病理过程.
- 微纤维相关蛋白4 (MFAP4) 是一个细胞外基质糖蛋白和一个整合素αVβ3/5/6连接体.
研究的目的:
- 研究MFAP4在视网膜新血管化和血管泄漏中的作用.
- 评估抗MFAP4抗体hAS0326的治疗潜力,用于治疗视网膜血管疾病.
主要方法:
- 单细胞转录组学在血管内皮细胞附近的细胞中确定了MFAP4的表达.
- 在体外研究中评估了hAS0326对内皮细胞运动性的影响.
- 在体内研究中使用了激光诱导的胆道神经血管化小鼠模型,链毒素诱导的视网膜病变和非人类灵长类动物视网膜病变模型来评估hAS0326的疗效.
主要成果:
- hAS0326通过防止MFAP4-整蛋白相互作用,在体外阻断了内皮细胞的运动.
- 在临床前模型中,静脉内膜hAS0326显著抑制了视网膜血管损伤区域,新血管体积和血管泄漏.
- 在非人类灵长类动物模型中,hAS0326的单剂量在至少12周内证明了持续的疗效.
- hAS0326 治疗丰富了与减少整蛋白结合相关的基因实体学术语.
结论:
- MFAP4与视网膜新血管化和血管泄漏有关.
- 抗MFAP4抗体hAS0326是新血管视网膜疾病的潜在治疗剂.
- hAS0326的机制涉及阻断整合素结合,减少内皮细胞活性和血管泄漏.
关键词:
在DME中,它是DME.在MFAP4中,MFAP4是MFAP4中的一个.糖尿病黄斑胀 糖尿病黄斑胀细胞外矩阵是细胞外矩阵.葡萄糖蛋白是一种葡萄糖蛋白质.整体的整体是整体的微纤维细胞相关蛋白质 4 4nAMD 的意思是新血管与年龄相关的黄斑变性.治疗性抗体治疗性抗体血管泄漏是因为血管泄漏在X射线晶体学研究中,更多相关视频
09:33An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment
Published on: September 13, 2016
7.1K
10:46Retinal Cryo-sections, Whole-Mounts, and Hypotonic Isolated Vasculature Preparations for Immunohistochemical Visualization of Microvascular Pericytes
Published on: October 7, 2018
10.0K
相关概念视频
01:27Open Angle Glaucoma: Treatment
389
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
389
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375